Merck Updates on Phase 3 Trial of Favezelimab-Pembrolizumab Combo in Colorectal Cancer
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the Phase 3 KEYFORM-007 trial, which investigated the fixed-dose combination of favezelimab (Merck’s anti-LAG-3 antibody) and…
BioAlberta and AxialBridge Partner to Help Alberta Life Sciences Companies Expand into the UK
BioAlberta is excited to announce a new partnership with AxialBridge as its operational and commercialization partner. This collaboration aims to assist Alberta-based biotechnology and MedTech companies in expanding their clinical…
eClinical Solutions Pioneers the Future of Drug Development at ENGAGE 2024 Conference
eClinical Solutions LLC, a global leader in digital clinical software and services, is set to host its sixth annual client and partner conference, ENGAGE 2024, on Thursday, October 10 and…
Phare Bio Secures Up to $27M from ARPA-H for AI-Driven Antibiotic Development
Phare Bio, in collaboration with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard’s Wyss Institute, has secured up to $27 million in funding from the Advanced…
BeiGene Updates on FDA Advisory Vote for PD-1 Inhibitors, Including TEVIMBRA, in ESCC and Gastric/GEJ Cancers
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized the positive…
FDA Approves Bristol Myers Squibb’s COBENFY for Adult Schizophrenia Treatment
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for treating schizophrenia in adults.…
New Study Assesses Awareness of High Breast Density as a Breast Cancer Risk Factor
In recognition of World Dense Breast Day on September 25, Bayer has announced a new study, published in Patient Preference and Adherence, that explores gaps in awareness and knowledge of…
BC Patients Neglected as Province Falls Short on Essential Medication Coverage
As British Columbians head to the polls on October 19, the Gastrointestinal Society is drawing attention to a critical issue: BC PharmaCare’s refusal to fund over 30 essential medications that…
Nashville Expansion Announced by Harrow
Tennessee Governor Bill Lee, along with Economic and Community Development Commissioner Stuart C. McWhorter and Harrow, Inc. CEO Mark L. Baum, announced today that Harrow is expanding its corporate headquarters…
Fujirebio Files FDA Submission for Alzheimer’s Plasma Diagnostic Test
Fujirebio has announced that its subsidiary, Fujirebio Diagnostics, Inc., has submitted the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test to the U.S. Food and Drug Administration…
Omnicell Names Nnamdi Njoku as Executive Vice President and Chief Operating Officer
Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming pharmacy care delivery, has announced the appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024.…
Medidata Strengthens Focus on Patient Experience with Launch of Patient Payments
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has introduced Medidata Patient Payments, a new solution designed to simplify the process…